MedTrace Logo

COVID-19 Vaccine Response in Treated MS Patients

NCT05060354 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2024-01-25

No results posted yet for this study

Summary

The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non-MS controls because the pivotal vaccine studies were conducted in non-MS healthy control groups in which there is significant clinical data and validated assays for antibody responses.

Conditions

Interventions

OTHER

Blood draw

Approximately 120 mL whole blood will be collected from each subject at each timepoint

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-09-15
Completion
2023-09-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05060354 on ClinicalTrials.gov